Autoimmune Encephalitis Misdiagnosis in Adults.


Journal

JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536

Informations de publication

Date de publication:
01 01 2023
Historique:
pubmed: 29 11 2022
medline: 12 1 2023
entrez: 28 11 2022
Statut: ppublish

Résumé

Autoimmune encephalitis misdiagnosis can lead to harm. To determine the diseases misdiagnosed as autoimmune encephalitis and potential reasons for misdiagnosis. This retrospective multicenter study took place from January 1, 2014, to December 31, 2020, at autoimmune encephalitis subspecialty outpatient clinics including Mayo Clinic (n = 44), University of Oxford (n = 18), University of Texas Southwestern (n = 18), University of California, San Francisco (n = 17), University of Washington in St Louis (n = 6), and University of Utah (n = 4). Inclusion criteria were adults (age ≥18 years) with a prior autoimmune encephalitis diagnosis at a participating center or other medical facility and a subsequent alternative diagnosis at a participating center. A total of 393 patients were referred with an autoimmune encephalitis diagnosis, and of those, 286 patients with true autoimmune encephalitis were excluded. Data were collected on clinical features, investigations, fulfillment of autoimmune encephalitis criteria, alternative diagnoses, potential contributors to misdiagnosis, and immunotherapy adverse reactions. A total of 107 patients were misdiagnosed with autoimmune encephalitis, and 77 (72%) did not fulfill diagnostic criteria for autoimmune encephalitis. The median (IQR) age was 48 (35.5-60.5) years and 65 (61%) were female. Correct diagnoses included functional neurologic disorder (27 [25%]), neurodegenerative disease (22 [20.5%]), primary psychiatric disease (19 [18%]), cognitive deficits from comorbidities (11 [10%]), cerebral neoplasm (10 [9.5%]), and other (18 [17%]). Onset was acute/subacute in 56 (52%) or insidious (>3 months) in 51 (48%). Magnetic resonance imaging of the brain was suggestive of encephalitis in 19 of 104 patients (18%) and cerebrospinal fluid (CSF) pleocytosis occurred in 16 of 84 patients (19%). Thyroid peroxidase antibodies were elevated in 24 of 62 patients (39%). Positive neural autoantibodies were more frequent in serum than CSF (48 of 105 [46%] vs 7 of 91 [8%]) and included 1 or more of GAD65 (n = 14), voltage-gated potassium channel complex (LGI1 and CASPR2 negative) (n = 10), N-methyl-d-aspartate receptor by cell-based assay only (n = 10; 6 negative in CSF), and other (n = 18). Adverse reactions from immunotherapies occurred in 17 of 84 patients (20%). Potential contributors to misdiagnosis included overinterpretation of positive serum antibodies (53 [50%]), misinterpretation of functional/psychiatric, or nonspecific cognitive dysfunction as encephalopathy (41 [38%]). When evaluating for autoimmune encephalitis, a broad differential diagnosis should be considered and misdiagnosis occurs in many settings including at specialized centers. In this study, red flags suggesting alternative diagnoses included an insidious onset, positive nonspecific serum antibody, and failure to fulfill autoimmune encephalitis diagnostic criteria. Autoimmune encephalitis misdiagnosis leads to morbidity from unnecessary immunotherapies and delayed treatment of the correct diagnosis.

Identifiants

pubmed: 36441519
pii: 2799083
doi: 10.1001/jamaneurol.2022.4251
pmc: PMC9706400
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

30-39

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS126227
Pays : United States
Organisme : NIA NIH HHS
ID : R56 AG055619
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R01 AG062562
Pays : United States
Organisme : Wellcome Trust
ID : 104079/Z/14/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V007173/1
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : K23 AG064029
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R01 AG031189
Pays : United States

Commentaires et corrections

Type : CommentIn

Auteurs

Eoin P Flanagan (EP)

Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Center for Multiple Sclerosis and Autoimmune Neurology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.

Michael D Geschwind (MD)

Department of Neurology, University of California, San Francisco (UCSF), San Francisco.

A Sebastian Lopez-Chiriboga (AS)

Department of Neurology, Mayo Clinic, Jacksonville, Florida.

Kyle M Blackburn (KM)

Department of Neurology, University of Texas Southwestern Medical Center, Dallas.

Sanchit Turaga (S)

Autoimmune Neurology Group, West Wing, Level 3, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.

Sophie Binks (S)

Autoimmune Neurology Group, West Wing, Level 3, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.

Jennifer Zitser (J)

Department of Neurology, University of California, San Francisco (UCSF), San Francisco.
Movement Disorders Unit, Department of Neurology, Tel Aviv Sourazky Medical Center, Affiliate of Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Jeffrey M Gelfand (JM)

Department of Neurology, University of California, San Francisco (UCSF), San Francisco.

Gregory S Day (GS)

Department of Neurology, Mayo Clinic, Jacksonville, Florida.
Washington University in St Louis, St Louis, Missouri.

S Richard Dunham (SR)

Washington University in St Louis, St Louis, Missouri.

Stefanie J Rodenbeck (SJ)

Department of Neurology, University of Utah, Salt Lake City.

Stacey L Clardy (SL)

Department of Neurology, University of Utah, Salt Lake City.

Andrew J Solomon (AJ)

Larner College of Medicine at the University of Vermont, Burlington.

Sean J Pittock (SJ)

Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Center for Multiple Sclerosis and Autoimmune Neurology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.

Andrew McKeon (A)

Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Center for Multiple Sclerosis and Autoimmune Neurology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.

Divyanshu Dubey (D)

Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Center for Multiple Sclerosis and Autoimmune Neurology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.

Anastasia Zekeridou (A)

Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Center for Multiple Sclerosis and Autoimmune Neurology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.

Michel Toledano (M)

Center for Multiple Sclerosis and Autoimmune Neurology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.

Lindsey E Turner (LE)

Graduate School of Health Sciences, Mayo Clinic College of Medicine, Rochester, Minnesota.

Steven Vernino (S)

Department of Neurology, University of Texas Southwestern Medical Center, Dallas.

Sarosh R Irani (SR)

Autoimmune Neurology Group, West Wing, Level 3, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH